Clinical Crossroads: AstraZeneca's Cancer Setback, Roivant's Lung Breakthrough, and Novo Nordisk's Pediatric Push

AstraZeneca's newly approved breast cancer drug Etcamah (camizestrant) failed its pivotal SERENA-4 trial as a first-line therapy, missing its primary endpoint of improving progression-free survival when combined with palbociclib in patients with ER-positive, HER2-negative advanced breast cancer who hadn't received prior systemic treatment.

Plain English

Despite getting FDA accelerated approval just last week for a narrower use in patients with drug-resistant tumors, the drug...